Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

GBGabriel BrisouCBCharles BrottierBNBertrand Nadel

Discussion

Loading...

Member takes

Overview

Single-cell profiling reveals tumor microenvironment alterations in follicular lymphoma patients post-Rituximab, suggesting Treg involvement in therapy resistance.

Key Points

  • Cytotoxic T cells were diminished in the bone marrow tumor microenvironment of follicular lymphoma patients, indicating immune dysfunction.
  • Single-cell profiling showed that certain T cell subsets correlate with poor clinical outcomes in low tumor burden patients.
  • Analysis revealed a persistent T-cell niche that may support cancer persister cells despite B-cell depletion from therapy.
  • Findings highlight the role of Treg and Tfh-like cells in lymphoid malignancies, pointing to potential therapeutic vulnerabilities.

Cite This Study

Brisou et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc96https://doi.org/10.1182/blood-2025-553
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Intratumoral B cell diversity in follicular lymphoma revealed by single-cell paired transcriptome and BCR sequencing2025
  2. 2Integrated single-cell and spatial analysis identifies T cell exhaustion and adhesion signatures in early follicular lymphoma transformation2025
  3. 3Spatially resolved profiling reveals the perifollicular border zone as a key immunologic hub in follicular lymphoma undergoing mosunetuzumab therapy2025
  4. 4Single-nucleus dissection of peripheral T-cell lymphomas reveals distinct microenvironmental ecosystems and therapeutic vulnerabilities2025
  5. 5Baseline T-cell fitness and subtype-specific CD19 loss as drivers of blinatumomab resistance in B-ALL2025